Saxenda® is a once-daily glucagon-like peptide-1 (GLP-1) analogue indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index of:1
- ≥30 kg/m2 (obese)
- ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes), hypertension, dyslipidaemia, or obstructive sleep apnoea.
Saxenda® should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight1.
Administration of Saxenda®1
- Saxenda® is for subcutaneous use only; it must not be administered intravenously or intramuscularly. Saxenda® is administered once daily at any time, independent of meals
- It should be injected in the abdomen, thigh or upper arm
- The injection site and timing can be changed without dose adjustment. However, it is preferable that Saxenda® is injected around the same time of the day
- If a dose is missed within 12 hours from when it is usually taken, the patient should take the dose as soon as possible. If there is less than 12 hours to the next dose, the patient should not take the missed dose and resume the once-daily regimen with the next scheduled dose. An extra dose or increase in dose should not be taken to make up for the missed dose
Saxenda® dose escalation
The starting dose of Saxenda® is 0.6 mg once daily. The dose should be increased to 3.0 mg once daily in increments of 0.6 mg with at least one week intervals to improve gastro-intestinal tolerability. If escalation to the next dose step is not tolerated for two consecutive weeks, consider discontinuing treatment. Daily doses higher than 3.0 mg are not recommended.1
If nausea is experienced, there are steps your patient can take to manage the symptom2:
- Eat smaller meals
- Stop eating when full
- Drink plenty of water
- Change the time of day Saxenda® is taken
There are also some things they can avoid, including2:
- Eating fatty or fried foods
- Eating spicy foods with strong smells
- High-fibre food
- Smoking or drinking alcohol
You should evaluate your patients’ progress with Saxenda® at 16 weeks:
*After 12 weeks on 3.0 mg maintenance dose, assess for ≥5% weight loss.
Showing patients how to inject Saxenda®
This video features instructions for your patient on how to:
- Attach the needle
- Check the flow of Saxenda®
- Select the correct dose
- Inject the dose
- Remove the needle
- Dispose of the needle.
6 easy steps to follow when administering the Saxenda® pen
Advise your patient that the Patient Information Leaflet has more detail on how to use their Saxenda® pen, including advice on how to care for pens.
Unused Saxenda® should be stored in a refrigerator (2-8°C); after first use, Saxenda® can be stored at room temperature (below 30°C) or in a refrigerator (2-8°C). Saxenda® should not be frozen.1
- Saxenda® Summary of Product Characteristics.
- Data on file. Tips that may help you manage some common side effects; 2017. Bagsværd, Denmark: Novo Nordisk A/S.
- Pi-Sunyer X, Astrup A, Fujioka K, et al; for the SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22 and supplementary appendix.